S&P 500 technical analysis review 8th April 2024

Last week highlighted the powerful long term trend that the index has been in for the past few months. Pushing up a breathtaking 27% in the latest move. A push this powerful has not been seen since the initial recovery from the pandemic crash. We highlighted last week the strength of the trend was even pushing down to the hourly chart as well. For this reason we again zoom into the hourly chart.

On this chart we have again a 200 period and 100 period linear regression channel, both of which had been containing all of the recent price action, until the break lower last week.

We highlighted last week that it would be difficult for the market to experience any real nervousness while these strong trends remained in place. But now we have our first test. Can the buyers return to enough scale to keep this bullish move in place, or is this the first warning sign?

We have thrown up a ghost projection of what the bears will want to see in the days ahead, namely an expected bounce from the oversold areas, but then a lack of follow through buying. Where projected price then drops to fresh lower lows. On any such move this would cause more jitters in the market as this would threaten the end of the powerful bullish trend.

As things stand however we can expect the buyers to be tempted back into the markets with enough scale to lift price action up towards 5,200 in fairly short order. What happens then will be highly watched. Can the buyers maintain control, or is this the first sign of the trend easing? We will know more in the coming days, with price action around 5,200 as key.

Aquis weekly movers: Cryptocurrency boost for Phoenix Digital

Phoenix Digital (LON: PNIX) is benefiting from the rise in cryptocurrency values. At the end of March 2024, NAV was £74.5m, equivalent to 7.38p/share. The NAV was 4.67p/share at the end of 2023. The NAV could be reduced by up to 1.1p/share due to a tax charge, but the shares, up 6.85% to 3.9p, are still trading at discount of more than two-fifths.

FALLERS

Selling on Friday led to a 51.9% slump in the Voyager Life (LON: VOY) share price to 4.5p. This comes at a time when a merger with Northern Leaf, which involves a share issue.

Cadence Minerals (LON: KDNC) has raised £500,000 at 3p/share. The new shares come with a warrant exercisable at 5p. The cash will be invested in the Amapa iron ore project in Brazil. The share price dived 20.9% to

Coinsilium Group (LON: COIN) has launched a new series of Web3 industry reports. These will provide a greater understanding of the Web3 space and the blockchain technology underpinning it. The share price fell 16.3% to 2.05p.

Brewer Adnams (LON: ADB) says it continues to explore ways of raising funds, including a share issue or sale of freehold assets. The share price dipped 13.3% to £19.50.

First York has put 12 new buses into services that feature the Equipmake (LON: EQIP) electric powertrain. This follows a trial with a convertible prototype vehicle. The share price declined 8% to 5.75p.

Tap Global Group (LON: TAP) chairman David Hunter bought an initial 148,347 shares at 1.35p each. The share price slipped 3.7% to 1.3p.

In the year to September 2023, spirits brands owner Rogue Baron (LON: SHNJ). Revenues grew from $146,000 to $284,000, while the loss increased from $606,000 to $$637,000, although it was lower before exchange differences. Net debt was $165,000 at the end of September 2023. The figures are for a period before than $1m invested in the main subsidiary by a US investor, which will have a 22.2% stake in that company. The share price fell 3.5% to 0.415p.

AIM weekly movers: Share buying in Tungsten West

0

There was significant trading in the shares in Cornish minerals company Tungsten West (LON: TUN) in the last three days of the week. There were 2.81 million shares traded on Thursday and 2.17 million shares on Friday. These are the largest numbers of shares traded on individual days since flotation in 2021. The share price jumped 137% to 3.2p. At the end of March, £1.6m was raised via a convertible, which will help finance a feasibility study.

Diagnostic tests developer genedrive (LON: GDR) benefited from NICE’s recommendation of the CYP2C19-ID test for genotype-guided clopidogrel treatment in the NHS. It is the preferred platform for UK point-of-care testing for the management of ischemic stroke and transient ischaemic attack patients. It is advised that these patients should have a genetic test before antiplatelet treatment. The share price improved 88.9% to 6.375p.

The Gelion (LON: GELN) share price continues to rise after yesterday’s announcement that the energy density testing of its lithium-sulphur battery technology shows that it far exceeds lithium-ion batteries. The 9.5 Ah pouch cell achieved an energy density of 395 Wh/kg, which 60% higher than lithium-ion batteries. This means that the batteries could be lighter and cheaper than rival technologies, as well as being made from more abundant materials, but there is some way to go to get to commercialisation. Gelion has cash of £7.5m. The share price is 86.9% higher at 28.5p, which is back above last November’s £4.4m fundraising price of 24p/share.

Horizonte Minerals (LON: HZM) says senior lenders have agreed to further waivers on interest payments until the end of April. If it is not extended further deferred interest payments for the past two quarters will become immediately due. The company’s Brazilian subsidiary is in a 60-day stay period against the enforcement of debt and security held by lenders and creditors and Horizonte Minerals is a guarantor of the debt. Any claim could force Horizonte Minerals into administration. The share price recovered 41.7% to 2.125p.

FALLERS

Redx Pharma (LON: REDX) is the latest AIM company that has decided to leave the junior market. A plan to reverse into a Nasdaq shell fell through last year and there is limited liquidity because two shareholders own more than 84% of the company. There are already enough votes to guarantee that the proposal is passed at the general meeting on 19 April. The share price dived 77% to 4.25p. Last October, £14.1m was raised at 26p/share. Management believes that it will be easier to raise money as a private company.

Portable oxygen technology developer Belluscura (LON: BELL) has suffered from the distraction and delays in the acquisition of standard list shell TMT Acquisition. This delayed the launch of the DISCOV-R product until June and the acquisition of components. Manufacturing is being moved to InnoMax in China. Cash flow breakeven has been delayed until the first quarter of 2025. A line of credit is being sought to cover non-recurring expenses. There is $3m in cash at the end of March 2024. The 2024 revenues will be lower than the previous range of $16m-$19m. There will be impairment charges in the 2023 accounts. The share price is 50% lower at 9.25p.

Infection protection technology developer Byotrol (LON: BYOT) shares have halved to 0.075p as they continue their fall ahead of the planned exit from AIM. The operations need to be restructured and costs reduced. Management believes there will be more flexibility as a private company. Asset Match will provide a matched bargain facility.

Perpetual has reduced its stake in semiconductors designer Sondrel (LON: SND) from 3.95% to less than 2.3%. The share price slumped 43.8% to 3.375p. Siemens sold its stake at 6p/share at the end of 2023.

FTSE 100 remains firmly lower after blowout Non Farm Payrolls report

The FTSE 100 was trading deep in red going into the weekend as concerns about interest rates sapped demand for equities.

Firmer oil prices increased interest rate tensions overnight, culminating in a softer start to European trade on Friday. Rates concerns were heightened after a blowout Non-Farm Payrolls pushed market expectations of the first US rate cut out to September from July.

Headline Non-Farm Payrolls increased by 303,000 versus expectations of 214,000. The number of jobs created is excellent news for the US economy but bad news for equity markets longing for a rate cut. The Unemployment rate fell to 3.8%, as expected.

US bond yields soared, and equities fell immediately after a headline jobs report that exceeded all Wall Street economist estimates.

The FTSE 100 started the session firmly lower and traded sideways, deep in the red, until the US Non-Farm Payroll release at 1.30pm.

“Storm clouds circled equity markets as investors started to fret about when interest rates would be cut given heightened inflationary pressures from oil hitting $90 a barrel and negative comments from a key figure,” said Russ Mould, investment director at AJ Bell before the jobs report was released.

The US jobs report did little to provide London’s leading index with any reprieve, and the FTSE 100 was trading down 0.8% at the time of writing.

The declines were broad, with only 4 of the FTSE 100’s constituents trading positively. Ocado was the top faller, down 7%, as the threat of higher interest rates hit technology sentiment.

Shell was one of the risers, adding just 0.5% as oil rose above $90 a barrel.

Housebuilders and UK property prices

The FTSE 100’s housebuilders were under pressure as UK property prices fell 1% in March from February. After five months of monthly gains, Halifax data showed a slowdown as mortgage rates remained elevated. Investors may be concerned that the UK housing market is not entirely out of the woods, with little indications of interest rate cuts in the immediate future.

“Affordability constraints continue to be a challenge for prospective buyers, while existing homeowners on cheaper fixed-term deals are yet to feel the full effect of higher interest rates. This means the housing market is still to fully adjust, with sellers likely to be pricing their properties accordingly,” said Kim Kinnaird, Director, Halifax Mortgages.

Persimmon fell 1.3%, and Taylor Wimpey was off by 1.5%.

Investing in fast-growing biotechnology companies with BB Biotech’s Dr Daniel Koller

The UK Investor Magazine was delighted to welcome Dr Daniel Koller, Head of the Investment Team at Bellevue Asset Management, the manager of Swiss-listed BB Biotech.

CHF2.5bn (£2.2bn) BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world’s largest investors in this sector with 30 years of experience. 

The shares of BB Biotech are listed on the SIX Swiss Exchange and the Frankfurt Stock Exchange. Its investments are focused on listed companies that are developing and commercializing novel drugs that offer sound value for the healthcare system.

BB Biotech’s holdings include Alnylam, Argenx, Moderna, and Biohaven.

We discuss the main biotech investment themes Daniel and his team observe, as well as specific recent investments.

Daniel explains BB Biotech’s investment approach and how they balance valuations with securing exposure to significant discoveries and commercialisation.

We explore the impact of the Inflation Reduction Act on big pharma and the small-cap biotech sector.

AIM movers: Strong second half at RUA and Steppe Cement loses market share

1

A strong second half at medical device technology developer RUA Life Sciences (LON: RUA) means that full year revenues were £2.2m – the same as the previous year. Margins have improved and operating costs fell £200,000 to £3.4m. There is £4m in cash. An initial development contract worth £100,000 has been awarded by a multinational. The share price recovered 20.5% to 13.25p, which is the highest it has been since the fundraising at 11p/share at the end of November.

The Gelion (LON: GELN) share price continues to rise after yesterday’s announcement that the energy density testing of its lithium-sulphur battery technology shows that it far exceeds lithium-ion batteries. The 9.5 Ah pouch cell achieved an energy density of 395 Wh/kg, which 60% higher than lithium-ion batteries. This means that the batteries could be lighter and cheaper and made from more abundant materials, but there is some way to go to get to commercialisation. Gelion has cash of £7.5m. The share price is 13.5% higher at 29.5p, which is back above last November’s £4.4m fundraising price of 24p/share.

PCI-Pal (LON: PCIP) chief executive James Barham bought 26,820 shares at 56.5p/share and non-exec Simon Wilson acquired 30,000 shares at 58.8p each. The share price increased 3.57% to 58p.

FALLERS

Steppe Cement (LON: STCM) plans to return 1.5p/share after a capital reduction is agreed by shareholders. That did not offset the disappointing trading statement from the Kazakhstan cement supplier. First quarter revenues fell from $10.8m to $8.4m due to a combination of lower sales and reduced selling price. The market decreased by 12%, but Steppe Cements market share fell from 12.7% to 11.5%.  The share price declined 17.1% to 17p.

Xeros Technology (LON: XSG) announced a fundraising late on Thursday. There has been £4.5m raised at 1.5p/share and up to £1m more could be raised via a retail offer that closes on 19 April. This will strengthen the balance sheet and provide cash to finance current contracts and commercialise the laundry technologies developer. The first royalty income could be received in the second half of 2024. EBITDA breakeven could be achieved before the end of the year. The share price is 13.5% to 1.6p.

Empyrean Energy (LON: EME) non-executive director John Laycock acquired 3.1 million shares at 0.6362p/share. Even so, the share price slipped 7.69% to 0.6p.

Macquarie has converted £500,000 of convertible bonds into shares in SkinBioTherapeutics (LON: SBTX) at 6.592863p/share. The 7.58 million shares will be purchased by existing shareholders. That leaves £890,000 of convertibles. The conversion comes after a rise in the share price over the past fortnight and it fell back 9.3% to 9.75p.

Alliance Pharma (LON: APH) has delayed its 2023 results from 9 April to 23 April because of delays to the audit. The share price dipped 4.1% to 36.825p.

Tekcapital’s Guident expands autonomous vehicle safety partnership with Auve Tech

Tekcapital’s Guident has announced the expansion of its strategic partnership with Auve Tech, an Estonian autonomous transportation company, with the launch of Auve Tech’s flagship MiCa autonomous shuttle into the US market.

Guident will integrate its Remote Monitor and Control Center solution into the MiCa shuttle to enhance the MiCa’s safety features by adding human-in-the-loop connectivity to the fixed-route transportation technology.

“With MiCa now officially ‘landed’ in the US for market entry, we are glad to join forces with Guident. Together, we are committed to enhancing the safety and efficiency of our MiCa AV shuttles with their advanced remote monitoring and control software. Based on the success in Japan and Europe, we eagerly anticipate rapid deployment of our innovative combined solution in the US and worldwide,” Johannes Mossov, Board Member at AuVe Tech OÜ.

A MiCa shuttle has been received at Guident’s headquarters and the integration process is fully underway. The new partnership and technology will be showcased at the grand opening of Guident’s new headquarters in Boca Raton, Florida, later in April.

“Since establishing our strategic partnership, we have been thrilled to collaborate with the Auve Tech team on several projects. We are particularly excited to achieve a significant milestone with Auve Tech’s entry into the US market coupled with the integration of our advanced teleoperation technology,” said Harald Braun, Executive Chairman and CEO at Guident.

The MiCa shuttle is described as ‘the world’s most compact and flexible level 4 autonomous shuttle.’ This is significant because most other companies developing Level 4 autonomous vehicle technology, including Alphabet, Volvo, and GM, have valuations in excess of a billion dollars.

Where the Auve Tech and Guident partnership breaks new ground is the established human-in-the-loop safety solution that allows a real person to take control of an autonomous vehicle should danger be detected.

A General Motors incident in which one of the company’s Cruise autonomous taxis dragged a woman after a collision in San Fransico is the perfect example of the benefits of a human-in-the-loop autonomous vehicle safety solution, such as Guident’s Remote Monitor and Control Center.

The California Department of Motor Vehicles suspended Cruise’s taxi license after the incident.

In the Cruise case, if the vehicle had access to a remote operator, they would have been able to step in and take control of the vehicle, possibly minimising the severity of the incident.

FTSE 350 housebuilders fall after Halifax says UK house prices fell 1% in March

The Halifax House Price Index’s release contributed to a fall in FTSE 350 housebuilder shares on Friday after the building society said average UK house prices fell 1% in the month of March.

Taylor Wimpey dropped 1.7%, Persimmon fell 1.4%, Barratt Developments shed 1.3%, and Crest Nicholson was off by 2%.

Although March prices dropped by 1% month-on-month, average UK house prices were up 2% on the quarter.

“UK house prices grew in March on a quarterly basis, by +2.0%, with annual growth slowing to +0.3%, from 1.6% in February. Compared to last month, the price of a UK property fell -1.0% or £2,908 in cash terms, with the average property now costing £288,430,” said Kim Kinnaird, Director, Halifax Mortgages.

“That a monthly fall should occur following five consecutive months of growth is not entirely unexpected particularly in view of the reset the market has been going through since interest rates began to rise sharply in 2022. Despite this house prices have shown surprising resilience in the face of significantly higher borrowing costs.”

As Kinnaird mentioned, house prices have been steadily increasing for five months, and as seasoned investors will be fully aware, no market moves in a straight line. The blip in housing prices has spurred a bout of profit-taking in FTSE 350 housebuilders on Friday after the sector rallied as house prices bottomed out last year.

A quarterly gain is an encouraging sign for the housing market, but with mortgage rates remaining elevated and many homeowners still to move onto mortgages at the new higher rates, the UK property market may still face some pain in the coming year.

“Affordability constraints continue to be a challenge for prospective buyers, while existing homeowners on cheaper fixed-term deals are yet to feel the full effect of higher interest rates. This means the housing market is still to fully adjust, with sellers likely to be pricing their properties accordingly,” Kinnaird said.

“Financial markets have also become less optimistic about the degree and timing of Base Rate cuts, as core inflation proves stickier than generally expected. This has stalled the decline in mortgage rates that had helped to drive market activity around the turn of the year.”

FTSE 100 jumps on stronger commodities, Non-Farm Payrolls eyed

The FTSE 100 was on a firmer footing on Thursday as stronger commodity stocks helped propel the index higher ahead of tomorrow’s Non-Farm Payrolls report.

Anglo American was the FTSE 100’s top gainer, with a gain of 3.3% as the broader FTSE 100 index added 0.45% to 7,972. Antofagasta and Fresnillo were also among the top risers as commodity prices continued to march higher.

“The FTSE 100 ticked higher on Thursday as US markets enjoyed a better session overnight,” said AJ Bell investment director Russ Mould.

“Miners were in demand as commodities prices continued to surge – an inflationary development which might provoke some nervousness about the fate of long-awaited interest rate cuts.”

Elsewhere, Entain enjoyed a 3% gain after announcing another senior management change – the Chairman will step down as the company continues to seek a new permanent CEO.

Suggestions that interest rates could stay higher for longer helped support the FTSE 100’s banks, with a good showing from Barclays, Standard Chartered, and NatWest.

Non-Farm Payrolls & Interest Rates

As the session progresses, attention will shift to tomorrow’s Non-Farm Payrolls and the ramifications for interest rates. Comments by the Federal Reserve Chair on the timing of rate cuts yesterday will heighten anticipation.

“Federal Reserve chair Jerome Powell warned yesterday of a risk of having to delay cuts thanks to stubborn inflationary pressures, although there was enough to reassure investors that a rate cut is coming at some point this year,” Russ Mould said.

Tomorrow’s data may see a return of ‘good news is bad news’ for global equities. If the jobs number comes in much better than expected, it will dash hopes of an interest rate cut soon and sour investor sentiment.

The Federal Reserve will be increasingly aware of the US economy’s resilience and stubbornly higher inflation. Strong Non-Farm Payrolls will support the view that the US can withstand higher rates, reducing the need to cut them.

Given the elevated levels of global equities, this scenario will be a concern for traders. Even the FTSE 100 has flirted with record highs in the recent melt-up.

Powell’s comments yesterday suggesting they will continue to digest data could act to exacerbate any market moves in reaction to the jobs report – a repricing to reflect rate cuts much later in the year could be sharp.

“Jerome Powell once again said that there was no rush to cut interest rates, although he did signal a cut would be coming this year, but that this is wholly dependent on economic progress,” said Sophie Lund-Yates, lead equity analyst, Hargreaves Lansdown.

We have seen risk aversion ahead of tomorrow’s number in equities earlier in the week. Should the jobs report be weaker than expected, one would expect stocks to pop higher at 1.30pm tomorrow.

AIM movers: Gelion testing success and ex-dividends

0

Energy density testing of the Gelion (LON: GELN) lithium-sulphur battery technology shows that it far exceeds lithium-ion batteries. The 9.5 Ah pouch cell achieved an energy density of 395 Wh/kg, which 60% higher than lithium-ion batteries. This means that the batteries could be lighter and cheaper and made from more abundant materials, but there is some way to go to get to commercialisation. Gelion has cash of £7.5m. The share price is 50.8% higher at 23p. Last November’s fundraising was at 24p/share.

Diagnostic tests developer genedrive (LON: GDR) is still benefiting from NICE’s recommendation of the CYP2C19-ID test for genotype-guided clopidogrel treatment in the NHS. It is the preferred platform for UK point-of-care testing for the management of ischemic stroke and transient ischaemic attack patients. It is advised that these patients should have a genetic test before antiplatelet treatment. The share price rose a further 49% to 7.75p.

Strong second half trading at Cavendish Financial (LON: CAV) meant that full year pro forma revenues, following the merger of finnCap and Cenkos, grew from £50.5m to £54m. Private and public M&A activity was buoyant. There was cash of £20.8m at the end of March 2024. Annualised savings of £7m have been made with more to come. The share price increased 30.1% to 11.25p.

Shares in Xtract Resources (LON: XTR) continue to rise following yesterday’s announcement of an option and joint venture agreement with Oval Mining to earn up to 70% of the Silverking copper mine in Zambia. Spending $500,000 over 18 months will earn 51% and spending $1m will earn a further 19%. There is historical data suggesting copper mineralisation. The share price is 10% ahead today at 1.1p.

FALLERS

Cirata (LON: CRTA), formerly WANdisco, says 2023 bookings fell to $7.2m from $11.5m. The business is being rebuilt after a period of turmoil. Management expects bookings to be in a range of $13m and $15m. The cash cost base of the data analytics company could be reduced to $23m. The share price fell 28.1% to 43.225p, which is a new low.

Cancer treatments developer Faron Pharmaceuticals (LON: FARN) is raising €4.8m at €1.50/share to satisfy the covenant requirements of its debt and this should provide enough cash until June. More cash will need to be secured to complete the phase II study for bexmarilimab. Cash burn for the first half of 2024 is expected to be €2.5m, declining to €2m in the second half. The share price declined 13.3% to 130p.

Evgen Pharma (LON: EVG) raised £51,760 from a retail offer of up to £1m. The offer price of 1p/share was the same as the placing that raised £850,000. The share price slumped 11.8% to 0.75p, which is an all-time low. Chronos Therapeutics is being acquired for £900,000 in shares at 1.44p each, which means that it will no longer be a single asset company. The company is changing its name to TheraCryf.

Antimicrobial treatments developer Ondine Biomedical Inc (LON: OBI) is preparing to enter the intensive care unit market in Canada. One in every eight of these patients develops an infection in their stay. Daily nasal decolonisation with the company’s Steriwave treatment can help to prevent infections. The share price slipped 5.41% to 8.75p.

Ex-dividends

Alpha Group International (LON: ALPH) is paying a final dividend of 12.3p/share and the share price rose 5p to £19.05.

BP Marsh (LON: BPM) is paying a dividend of 2.68p/share and the share price slipped 2.5p to 496p.

Kitwave (LON: KITW) is paying a final dividend of 7.45p/share and the share price fell 5p to 356.5p.

Nexus Infrastructure (LON: NEXS) is paying a dividend of 2p/share and the share price declined 3p to 77.5p.

Pebble Group (LON: PEBB) is paying a final dividend of 1.2p/share and the share price is unchanged at 65p. Real Estate Investors (LON: RLE) is paying a dividend of 0.63p/share and the share price dived 1p to 32.5p.